Bioresorbable coronary scaffolds: A novel device-based solution in search of its clinical need

摘要

In this focused issue of the European Heartjournal, Iqbal et al. provide a comprehensive and thoughtful review of lessons learned from relevant pre-clinical and early clinical evaluations of bioresorbable coronary scaffolds, concentrating on the one brand (everolimus-eluting Absorb device, BVS, Abbott Vascular) that has undergone the largest and most detailed investigations thus far. These cumulative observations were performed in small selected series, but have built up confidence in the clinical performance of BVS following extensive, carefully reported, and sequential (up to 3 years) multimodality interrogations using multislice coronary computed tomography imaging, invasive coronary angiography and its quantitation, intravascular ultrasound and tissue backscatter analysis, optical coherence tomography imaging (OCT), and coronary vasomotor testing.